[January 10, 2013]

BioClinica, Inc. to Participate in Upcoming Industry Events and Demonstrate Global Technology-Enhanced Clinical Trial Management Capabilities

BioClinica^®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced that members of its team will attend, participate in and lead discussions at several upcoming industry conferences in January, February, and March. BioClinica experts will share industry trends and demonstrate the company's suite of eClinical Solutions and Imaging Core Lab Services. The conferences include:

Intended for leaders in process improvement, product design, and Lean Six Sigma, the Design for Six Sigma and Process Improvement Event is a one-day program focused on defining good design, understanding the best tools of design, and identifying individuals in the Philadelphia area who are successfully applying design principles. The event will feature presentations and discussions on design as well as interactive workshops. BioClinica's Process Excellence Lead, Michael H. Ensby, MS, 6s MBB, PMP, will present a session titled "Developing a Heuristic for Quality Design and Prototyping" at 9:30 a.m.

Arena International's Outsourcing in Clinical Trials West Coast conference aims to formulate a more proactive approach to perfecting sponsor-vendor relationships by qualifying the importance of strategic vendor selection and management as well as identifying key changes and advancements within the pharmaceutical industry. The conference will document the level of growth in new markets and show how outsourcing helps boost productivity. As an event exhibitor, BioClinica representatives will showcase the company's industry-leading eClinical solutions and Imaging Core Lab services.

DIA's Annual EuroMeeting is a global conference that attracts over 3,000 attendees from more than 50 countries. It brings together professionals from the biopharmaceutical industry, contract research and service organizations, academic research centers, regulatory agencies and health ministries as well as delegates from patient organizations to network and discuss the future of pharmaceutical drug development. As an event exhibitor, BioClinica representatives will be on hand to demonstrate the company's industry-leading eClinical solutions and Imaging Core Lab services.

CBI's ClinTech is designed to help pharmaceutical companies and contract research organizations implement, manage, and integrate systems to advance clinical trials. The conference will feature separate technology-driven tracks focused on Clinical Trial Management Systems (CTMS), Electronic Trial Master File (eTMF) solutions, data portals, and Electronic Data Capture (EDC). As an event sponsor, BioClinica representatives will demonstrate the company's industry-leading eClinical solutions.

Follow BioClinica on the Trial Blazers blog at http://www.bioclinica.com/blog, and on Twitter (News - Alert) at http://twitter.com/bioclinica.

About BioClinica, Inc.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management services. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, Microsoft (News - Alert) Office-Smart clinical trial management, and clinical supply chain forecasting and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With more than 20 years of experience and over 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.

[ Back To Technology News's Homepage ]